Chair
CEO at Mission Therapeutics focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need.
Bioqube Ventures
Principal at Bioqube Ventures focusing on sourcing, financing and developing innovative therapeutic assets and technologies.
Novo Seeds
Principal at Novo Holdings and part of the Novo Seeds team focusing early-stage financing and development of strong and competitive companies.
Head of Discovery & Co-founder
Nick has extensive experience in antibody characterization and has worked within the field of complement research for more than 15 years.
CEO & CSO
Seasoned R&D executive and scientific leader with over two decades of experience in antibody development from immuno-oncology and autoimmune disease drug discovery programs.
Senior Investment Manager
Senior Investment Manager at Korys focusing on investments in companies developing science-based solutions that prevent or treat diseases.
Antibody enthusiast and molecular Immunologist
Formerly served as SVP Antibody Research and Technology at Genmab. Pioneered IgG4 biology and IgG1-complement interactions leading to groundbreaking insights in antibody biology. Co-inventor of numerous therapeutic antibodies, including FDA-approved RYBREVANT® (amivantamab) and EPKINLY® (epcoritamab). Also co-inventor of the bispecific antibody platform DuoBody® and effector function-enhanced HexaBody® and HexElect® technologies.
Rheumatologist and Immunologist
Brian recently served as SVP and CMO at Nektar Therapeutics. Previous Head of the Inflammation Therapeutic Area and Vice President, Head of Medical Sciences at Amgen. Trained rheumatologist and immunologist and previously Professor of Medicine at the University of Colorado.
Patent attorney and transactional lawyer
Previously member of the management team at Ablynx, responsible for IP strategy, building a strong patent estate and involved in negotiating various partnerships with leading pharma companies. Ablynx was acquired by Sanofi in 2018 for $4.8B.
Complementologist and structural biologist
Gregers has more than 25 years of experience within the complement system and structural biology and has served as an advisor for several pharmaceutical companies with complement targeting drugs in their pipeline. Gregers is currently Professor at the department of Molecular Biology and Genetics at Aarhus University where he is leading his own research group.
Commit Biologics ApS
Universitetsbyen 83
8000 Aarhus C, Denmark
© 2022 Commit Biologics. All rights reserved.